The average one-year price target for Veru (NasdaqCM:VERU) has been revised to $25.50 / share. This is an increase of 11.11% from the prior estimate of $22.95 dated January 11, 2026. The price target ...

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of ...